华法林

CHF合并AF患者阿司匹林使用率为51.6%（227/440），华法林使用率为8.6%（38/440）。

The usage rate of aspirin was 51.6 % , and warfarin was 8.6 % .

华法林（Warfarin）是临床广泛应用的一种常用的抗凝血药，主要用于预防和治疗体内的各种凝血疾病。

Warfarin is an anticoagulant widely used in the treatment and prophylaxis of various thromboembolic disorders .

华法林的Roberts应用方法治疗心肌梗死后脑梗死的研究

Study of Roberts ' Warfarin loading protocol on cerebral infarction after myocardial infarction

目的建立华法林含量测定的高效液相色谱（HPLC）方法，并以此方法考察比较4个不同厂家华法林片的溶出度。

OBJECTIVE To establish a high performance liquid chromatography ( HPLC ) method for determining the dissolubility of warfarin tablets produced by four manufactories in vitro .

观察SSS重建围手术期以华法林和肝素为组合的抗血栓疗效。

To observe the effect of heparin and warfarin as anti - coagulation drug .

在家中服用华法林的、INR值升高的非ST段抬高性心肌梗死患者紧急治疗是否增加出血风险？

Is Bleeding Risk Augmented With Acute Therapies Across Increasing INR Levels Among NSTEMI Patients on Home Warfarin Therapy ?

华法林治疗深静脉血栓不同初始剂量INR值变化的调查

The INR Change About Different Dose Warfarin Treatment for DVT

部分服用华法林的患者没有做到INR检测的同步，这对于患者是有危险的。

The INR were not tested in some AF patients with warfarin therapy simultaneously .

D-二聚体、Hs-CRP检测在华法林治疗2型糖尿病伴不稳定型心绞痛中的临床研究

Clinical Application of C-reactive Protein and D-dimer Assays in Type 2 Diabetes Patients with Unstable Angina During Oral Warfarin Therapy

目的：观察华法林抗凝治疗短暂性脑缺血发作（TIA）的安全性和疗效。

AIM : To evaluate the safety and efficiency of oral anticoagulation in patients with transient ischemic attack ( TIA ) .

目的观察华法林的Roberts应用方法抗凝治疗心肌梗死后脑梗死的安全性和有效性。

Objective It is to observe the safety and effect of Roberts ' Warfarin loading protocol on cerebral infarction after myocardial infarction .

目的探讨华法林及适合的INR预防非瓣膜病房颤血栓栓塞。

Objective To study Warfarin and appropriate INR in order to prevent thromboembolism of non-valves cardiac disease .

心脏瓣膜置换术后患者的华法林目标INR范围略高于其他华法林适应症患者。

The target INR range for HVR patients is higher than that of those with other warfarin indications .

目的：对8例心脏瓣膜置换病人po华法林5～10mg后的对映体药动学过程进行评价。

OBJECTIVE : To evaluate pharmacokinetics of warfarin enantiomers in 8 patients with cardiac valve replacement after first oral administration of 5 ~ 10 mg recemic warfarin .

结论INR保持在1.5~2.0之间的低剂量华法林在房颤病人中的使用是安全有效的。

Conclusions It is safe and effective for patients with atrial fibrillation to take low dosage warfarin with INR keeping 1.5-2.0 .

最后，研究者总结道：WATCHMAN装置是可替代华法林预防房颤患者发生卒中的有效措施。

The researchers concluded that the WATCHMAN is an effective alternative to warfarin therapy for preventing stroke in patients with atrial fibrillation .

结论老年持续性心房颤动患者应用华法林抗凝治疗时，使INR稳定于1.8~2.5既有效又安全。

Conclusion Warfarin for the treatment of elderly persistent atrial fibrillation is both efficient and safe when INR can be maintained between 1.8-2.5 .

结论：持续性房颤患者应用华法林抗凝治疗时，INR维持在2～3范围可能是安全的；

Conclusions : It is safe for the patients with persistent atrial fibrillation using warfarin while the INR ranges from 2 to 3 ;

安泰保险（AetnaInc.）旗下独立慈善机构安泰基金会（AetnaFoundation）也在赞助一项研究&每天抽奖是否足以激励人们坚持服用华法林（warfarin）。

Aetna Foundation , the independent philanthropic arm of insurer Aetna Inc. , also is sponsoring a study of whether daily lotteries motivate people to stick to warfarin .

非瓣膜病房颤或房扑患者应用不同起始剂量华法林对INR达标速度的影响

The Effect of Different Initial Warfarin Dosages on the Time of Target International Normalized Ratio in Patients with Nonvalvular Atrial Fibrillation or Atrial Flutter

方法86例心脏机械瓣膜置换术患者，按术后使用不同的抗凝方案分为4组。华法林1组：术后第1d开始口服华法林；

Methods Eighty-six patients with mechanical valve replacement were divided into four groups according to different anticoagulation methods , warfarin group 1 : warfarin was given from the 1st day after operation ;

方法在心脏机械瓣膜替换术后不同时间段定期复查凝血酶原时间（PT）及凝血酶原时间比值（PTR），按其正常值的1~1.5倍给以华法林治疗。

Method To check the prothrombin time ( PT ) and prothrombin time ratio ( PTR ) in deferent period , make the PT 1 ~ 1.5 times than its normal result using warfarin .

目的探讨老年持续性心房颤动患者应用华法林抗凝治疗的有效性、安全性及国际标准化比值（INR）范围。

Objective To explore the efficacy , safety and range of international normalized ratio ( INR ) of warfarin in the treatment of elderly persistent atrial fibrillation .

结论非瓣膜病房颤采用华法林抗凝治疗并注意监测INR，使INR保持在1.6~2.5之间，是安全有效的。

Conclusion It is safe and effective when using Warfarin to prevent thromboembolism of non-valves cardiac disease , on condition that the value of INR is kept between 1.6 and 2.5 .

方法：将非瓣膜病性心房颤动患者117例应用华法林分进行抗凝治疗并为两组：抗凝强度国际标准化比率（INR）1.6～2.4组，67例；

Methods : 117 patients with nonvalvular atrial fibrillation under the anticoagulant therapy of warfarin were allocated into 2 groups : 67 patients in group ( international normalized ratio 1.6 ~ 2.4 ) ;

方法：将137例机械瓣置换术后口服华法林抗凝的患者，根据抗凝强度（INR值）分成3组：A组（1.5≤INR<2.0），44例；

Methods : A total of 137 patients received cardiac valve replacement were randomized into 3 groups according to anticoagulation intensity ( INR ): group A ( INR 1.5 ~ 1.99 ), 44 patients ;

结果：华法林用量为2.54±0.7（1～6）mg/d，治疗维持国际标准化率（INR）在2～3范围时，轻度出血率为3.15%，经相关处理并调低INR值，所有出血均停止；

Results : The dose of warfarin was 2.54 ± 0.7 ( 1 ~ 6 ) mg / d and the INR ranged from 2 to 3 , the rate of slight hemorrhage was 3.15 % .

探讨了华法林对BSA荧光的猝灭机理，测定了不同温度下华法林与BSA的结合常数和结合位点数，并根据热力学常数确定了两者的作用力类型。

The quenching mechanism of fluorescence of BSA by warfarin was discussed . The binding constants and binding numbers of warfarin and BSA were determined at different temperatures , respectively . According to the thermodynamic parameters , the main sorts of binding force was obtained .

目的1.经本实验回顾，统计出宁夏地区2003年-2009年瓣膜置换术后，INR治疗范围口服华法林的剂量及抗凝相关并发症的发生率。

Objective 1.After review of the case , and further the statistics in the region in 2003 - 2009 after valve replacement , INR therapeutic range of warfarin dose and the incidence of anticoagulant-related complications . 2 .

证实以下非遗传因素可影响华法林稳定剂量：体表面积、年龄、合用导致INR升高的药物数量、吸烟、术前卒中史、高血压病等。

We verified that the following non-genetic factors were minor determinants of warfarin stable dosage : body surface area , age , number of increasing INR drugs , smoking habit , preoperative stroke history and hypertension . 3 .